Prognostic significance of HIF-1α polymorphisms in transitional cell carcinoma of the bladder

International Journal of Cancer

Volumn 122, Issue 6, 2008, Pages 1297-1302

  Nadaoka, Junichi ^a   Horikawa, Yohei ^a   Saito, Mitsuru ^a   Kumazawa, Teruaki ^a   Inoue, Takamitsu ^a   Narita, Shintaro ^a   Yuasa, Takeshi ^a   Satoh, Shigeru ^a   Nishiyama, Hiroyuki ^b   Ogawa, Osamu ^b   Tsuchiya, Norihiko ^a   Habuchi, Tomonori ^a  

^a AKITA UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

HIF 1 ; Polymorphism; Transitional cell carcinoma, bladder

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; VASCULOTROPIN;

ADULT; ALLELE; ARTICLE; BLADDER CANCER; BLADDER CARCINOMA; CANCER GROWTH; CANCER SURVIVAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; CYSTECTOMY; DISEASE FREE SURVIVAL; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INCIDENCE; JAPANESE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSITIONAL CELL CARCINOMA;

BASE SEQUENCE; CARCINOMA, TRANSITIONAL CELL; DNA PRIMERS; GENOTYPE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; URINARY BLADDER NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 39649104577     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23256     Document Type: Article

References (16)

1. Pouyssegur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006;441:437-43.
2. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res 1999;59:5830-5.
3. Charlesworth PJ, Harris AL. Mechanisms of disease: angiogenesis in urologic malignancies. Nat Clin Pract Urol 2006;3:157-69.
4. Canoglu A, Gogus C, Beduk Y, Orhan D, Tulunay O, Baltaci S. Microvessel density as a prognostic marker in bladder carcinoma: correlation with tumor grade, stage and prognosis. Int Urol Nephrol 2004;36:401-5.
5. Kizaka-Kondoh S, Inoue M, Harada H, Hiraoka M. Tumor hypoxia: a target for selective cancer therapy. Cancer Sci 2003;94:1021-8.
6. Bardos JI, Ashcroft M. Hypoxia-inducible factor-1 and oncogenic signalling. Bioessays 2004;26:262-9.
7. Clifford SC, Astuti D, Hooper L, Maxwell PH, Ratcliffe PJ, Maher ER. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C Rbx1 and HIF-1α in renal cell carcinoma. Oncogene 2001;20:5067-74.
8. Tanimoto K, Yoshiga K, Eguchi H, Kaneyasu M, Ukon K, Kumazaki T, Oue N, Yasui W, Imai K, Nakachi K, Poellinger L, Nishiyama M. Hypoxia-inducible factor-1α polymorphisms associated with enhanced transactivation capacity, implying clinical significance. Carcinogenesis 2003;24:1779-83.
9. Chau CH, Permenter MG, Steinberg SM, Retter AS, Dahut WL, Price DK, Figg WD. Polymorphism in the hypoxia-inducible factor 1α gene may confer susceptibility to androgen-independent prostate cancer. Cancer Biol Ther 2005;4:1222-5.
10. Fransen K, Fenech M, Fredrikson M, Dabrosin C, Soderkvist P. Association between ulcerative growth and hypoxia inducible factor-1α polymorphisms in colorectal cancer patients. Mol Carcinog 2006;45: 833-40.
11. Theodoropoulos VE, Lazaris AC, Kastriotis I, Spiliadi C, Theodoropoulos GE, Tsoukala V, Patsouris E, Sofras F. Evaluation of hypoxia-inducible factor 1α overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma. BJU Int 2005;95:425-31.
12. The Japanese Urological Association and the Japanese Society of Pathology. General rule for clinical and pathological studies on bladder cancer, 2nd edn. Tokyo: Kanehara-Shuppan, 1993.
13. Mostofi FK, Sobin LH, Troloni H. Histological typing of urinary bladder tumors, in International Histological Classification of Tumors, No. 10. Geneva: World Health Organization, 1973;15-34.
14. Union Internationale Contre Cancer. Classification of malignant tumors, 5th edn. Berlin: Springer-Verlag, 1997.
15. Konac E, Onen HI, Metindir J, Alp E, Biri AA, Ekmekci A. An investigation of relationships between hypoxia-inducible factor-1α gene polymorphisms and ovarian, cervical and endometrial cancers. Cancer Detect Prev 2007;31:102-9.
16. Hebert C, Norris K, Parashar P, Ord RA, Nikitakis NG, Sauk JJ. Hypoxia-inducible factor-1α polymorphisms and TSC1/2 mutations are complementary in head and neck cancers. Mol Cancer 2006;5:3.